Caricamento...
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor...
Salvato in:
| Pubblicato in: | NPJ Breast Cancer |
|---|---|
| Autori principali: | , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6336880/ https://ncbi.nlm.nih.gov/pubmed/30675515 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-018-0097-z |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|